Immunoglobulin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii)

Beata Ujvari1,2, Rodrigo Hamede3, Sarah Peck2,4, David Pemberton4, Menna Jones3, Katherine Belov2 & Thomas Madsen1,5,6

Immunoglobulins such as IgG and IgM have been shown to induce anti-tumour cytotoxic activity. In the present study we therefore explore total serum IgG and IgM expression dynamics in 23 known-aged Tasmanian devils (Sarcophilus harrisii) of which 9 where affected by Devil Facial Tumour Disease (DFTD). DFTD is clonally transmissible cancer that has caused massive declines in devil numbers. Our analyses revealed that IgM and IgG expression levels as well as IgM/IgG ratios decreased with increasing devil age. Neither age, sex, IgM nor IgG expression levels affected devil DFTD status in our analyses. However, devils with increased IgM relative to IgG expression levels had significantly lower DFTD prevalence. Our results therefore suggest that IgM/IgG ratios may play an important role in determining devil susceptibility to DFTD. We consequently propose that our findings warrant further studies to elucidate the underpinning(s) of devil IgM/IgG ratios and DFTD status.

Since its first sighting in 1996, the Tasmanian Devil Facial Tumour Disease (DFTD) has caused massive (>85%) population declines of Tasmanian devils (Sarcophilus harrisii), hence questioning the long-term survival of this iconic species. This highly contagious and clonally transmissible cancer is spread among individual devils via biting during social interactions. DFTD cells are able to avoid host immune recognition by down-regulating MHC expression. Metabolic failure, tumour related cachexia and metastases result in devil death within 6 to 9 months of the emergence of the first lesions.

Presently, no therapy to reduce the devastating effects of DFTD has been developed. Numerous studies have, however, demonstrated that IgM antibodies provide extended tumour immunosurveillance as well as anti-tumour cytotoxic activity in other organisms, and IgM antibody therapy has been shown to reduce neuroblastoma and melanoma in humans. In the present study we therefore investigate the effects of total serum IgG and IgM antibody expression dynamics on DFTD prevalence in the world's largest surviving marsupial carnivore; the Tasmanian devil.

**Results**

Total serum IgM and IgG expression levels decreased with increasing devil age, and a single factor heterogeneity of slopes test with antibody as factor, age as covariate and antibody expression as dependent variable revealed a steeper age-specific decline in IgM compared to IgG expression levels ($F_{3,42} = 24.24, p < 0.0001$; age: $F_1 = 57.46, p < 0.0001$; antibody: $F_1 = 6.29, p = 0.016$; slope: age*antibody: $F_1 = 9.0, p = 0.0046$, Fig. 1). Moreover, using a simple linear regression our analyses also revealed that IgM/IgG expression ratios decreased with increasing devil age ($r^2 = 0.70, p < 0.0001$, N = 23; Fig. 2).

Using logistic regression we subsequently investigated whether the independent effects of devil age, sex, IgG and IgM expression as well as IgM/IgG ratio, and any of the possible two-way interactions between the five factors affected devil DFTD status. Following Quinn and Keough backward elimination was set at $P > 0.2$ which revealed that only devil IgM/IgG expression ratio had a significant effect on Devil DFTD status (Wald test, final
model IgM/IgG ratio: $\chi^2 = 5.90, p = 0.015, df = 1$). Thus, devils with increased IgM relative to IgG expression levels had significantly lower DFTD prevalence (Fig. 3).

### Discussion

IgM antibody titers have been shown to increase with advancing age in numerous vertebrates and IgM dynamics has therefore been suggested to play a crucial role in maintaining immunocompetence during the ageing process\(^{13}\). The decline of IgM expression levels with increasing age suggests that devils are subjected to a significant age-related decline in immune function.

Although an experimental study showed that some devils are able to mount a specific IgG immune response to DFTD\(^{14}\) we did not observe any significant effects of IgG expression levels on DFTD status. As mentioned above, IgM antibodies have been shown to induce anti-tumour cytotoxic activity but in spite of this we did not detect any association between devil IgM expression levels and devil DFTD status.

DFTD prevalence has been shown to increase with increasing devil age\(^1\). However, the results from the present study demonstrate that only IgM/IgG expression levels, and not age, had a significant impact on devil DFTD
status. In humans IgM/IgG antibody ratio has been shown to play a crucial role in resistance to diseases such as cerebral small vessel disease\textsuperscript{15}. Moreover, in mice challenged by melanoma cells, increased IgM relative to IgG titers resulted in regressed tumour growth whereas decreased IgM relative to IgG titers caused aggressive tumour progression\textsuperscript{4}. Although we can not rule out that DFTD results in a reduction in IgM relative to IgG titers, the results from the present study mirror those obtained in mice i.e. increased IgM relative to IgG expression levels significantly reduced devil DFTD prevalence, highlighting the importance of IgM/IgG ratios in cancer aetiology. We consequently propose that our findings warrant further studies to elucidate the mechanisms of total IgM/IgG ratios and devil DFTD prevalence.

Although active immunotherapy has not yet become the “magic bullet” in cancer treatment\textsuperscript{16}, the results from the present study suggest the importance of IgM/IgG ratios in devil carcinogenesis. The development of anti-tumour vaccines that enhance the production of IgM relative to IgG antibodies and/or direct treatment with IgM antibodies such as PAT-SM6\textsuperscript{17} may therefore become an important component in combating the devastating effects of DFTD on devil population demography.

Materials and Methods

Animals, age and DFTD scoring. Twenty three devils (10 females and 13 males) were blood sampled (500 μl/sample) in March and May 2012 at “West Pencil Pine”, 15 km to the west of Cradle Mountain National Park in north-west Tasmania. Devil age was determined by using 20\textsuperscript{th} of March as the mean birth date and represented 8 age groups ranging from 12 to 48 months (for further details on aging see Hamede et al.\textsuperscript{17}). Disease status was assessed by visual inspection of tumours and/or by histopathological examination of biopsies collected from tumours\textsuperscript{17}. Of the 23 devils, 14 showed no clinical signs of being infected whereas 9 were confirmed to be infected by DFTD. The methods were carried in accordance with the approved guidelines of the University of Tasmania's Animal Ethics Committee (A0010296), and all experimental protocols were approved by the University of Tasmania’s Animal Ethics Committee (A0010296).

RNA extraction and quantifying IgM and IgG expression by quantitative RT-PCR (qRT-PCR). RNA was extracted from blood samples using the RNeasy Protect Animal Blood Kit (Qiagen, Germantown, MD). Genomic DNA was removed from the RNA samples by the DNAse I AMPD1 kit (Sigma, St. Louis, MO) and cDNA was synthesized with the QuantiTect Reverse Transcription Kit (Qiagen, Germantown, MD).

Immunoglobulin heavy chain constant region segments were identified and sequenced as part of a previous study\textsuperscript{18} from the whole genome sequence of the Tasmanian devil available in the Ensembl database (DEVIL7.0, GCA_000189315.1)\textsuperscript{19}. Only one transcript variant of IgM and IgG heavy chain constant regions have been identified the Ensembl database (DEVIL7.0, GCA_000189315.1)\textsuperscript{19}. Gene specific primers were designed across exons of IgG (exon3 – exon4) and IgM (exon1 – exon2) heavy chain constant regions to avoid amplification of genomic DNA. The amplified cDNA products were cloned (using Topo-Ta Cloning (ThermoFisher Scientific, MA, USA) and sequenced using Sanger Sequencing to verify that functional IgM, IgG and RPS29 transcripts were amplified. The sequences have been deposited to GenBank under accession numbers: Saha-IgG: KU664590, Saha-RPS29: KU664591 and Saha-IgM: KU664592. Additionally melt curve analyses were conducted to confirm the lack of genomic DNA and primer dimers in the reaction (Supplementary Material).

cDNA was amplified without using primers from variable region sequences, thus allowing for a representative sampling of immunoglobulin genes expressed by circulating B cells. Our results therefore provide a “snapshot” of the levels of circulating IgG and IgM antibodies at the time of sampling.

Specific IgG and IgM primers were designed using the Primer3Plus website (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi); IgG primers: qIgG-F: 5’-CAG GTG ATC AGC ACT CTC TCT G-3’,
REST21 was used to calculate the normalized fold change of target compared with the reference gene. The program and controls containing no cDNA samples were run alongside the reactions to confirm that no genomic DNA was amplified, and the lack of primer dimers in the reactions, respectively (Supplementary Material). The program ear quantifiable range of the appropriate standard curves. Controls containing no reverse transcriptase enzymes, 1.04 and RPS29: 1.00). All samples were run in quadruplicate, and all Cq values for unknowns fell within the linear quantifiable range of the appropriate standard curves. Controls containing no reverse transcriptase enzymes, and controls containing no cDNA samples were run alongside the reactions to confirm that no genomic DNA was amplified, and the lack of primer dimers in the reactions, respectively (Supplementary Material). The program REST21 was used to calculate the normalized fold change of target compared with the reference gene.

Similar to the IgG and IgM primers, gene specific primers were designed across exons of RPS29 (exon1 – exon2, only one transcript identified): RPS29-F: 5′-ATG GGT CAT CAG CTC TAC-3′, RPS29-R: 5′-AGG CCG TAT TTT CCG ATT AG-3′). Quantitative RT-PCR was conducted on the RotorGene6000 (Qiagen, Germantown, MD). Standard curves (r2 > 0.99) contained five dilutions from the dilution series with a linear dynamic range of at least 3 orders of magnitude. PCR efficiencies ranged between 0.94 and 1.07 (IgG: 0.94, IgM: 1.04 and RPS29: 1.00). All samples were run in quadruplicate, and all Cq values for unknowns fell within the linear quantifiable range of the appropriate standard curves. Controls containing no reverse transcriptase enzymes, and controls containing no cDNA samples were run alongside the reactions to confirm that no genomic DNA was amplified, and the lack of primer dimers in the reactions, respectively (Supplementary Material). The program REST21 was used to calculate the normalized fold change of target compared with the reference gene.

Statistical analyses. IgG and IgM expressions levels were ln-transformed to normalize distributions and to equalize variance across age groups. Analyses were carried out using JMP version 5.1.

References

1. Jones, M. Life-history change in disease-ravaged Tasmanian devil populations. Proc. Natl. Acad. Sci. USA 105, 10023–10027 (2008).
2. Belov, H. V. et al. The role of the Major Histocompatibility Complex in the spread of contagious cancers. Mamm. Genome 22, 83–90 (2011).
3. Siddle, H. V. et al. 2013. Reversible epigenetic down-regulation of MHC molecules by devial facial tumour disease illustrates immune escape by a contagious cancer. Proc. Natl. Acad. Sci. USA 110, 5103–5108 (2013).
4. Ravindranath, M. et al. Ratio of IgG IgM antibodies to Stabyl Lewis′ and GM, correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Int. J. Cancer, 75, 117–124 (1998).
5. Schwartz-Albiez, R., Monteiro R. C., Rodriguez, M., Binder, C. J. & Shoenfeld, Y. Natural antibodies intravenous immunoglobulin and their role in autoimmunity cancer and inflammation. Clin. Exp. Immunol. 158, Suppl 1, 43–50 (2009).
6. Poggi, A. & Raffaella Zocchi, M. Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment. OncolImmunology 12, 214–216 (2012).
7. Oaks, M., Taylor, S. & Shaffer, J. Autoantibodies targeting tumor-associated antigens in metastatic cancer. OncolImmunology 26, e24841 (2013).
8. Rasche, L. et al. The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78. Plos One 8, e63414 (2013).
9. Rodriguez-Zharbenko, N. et al. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties. Eur. J. Immunol. 43, 826–837 (2013).
10. Ettmann, R. Treatment of neuroblastoma with human natural antibodies. Autoimmun. Rev. 7, 496–500 (2008).
11. Hensela, F., Ecksteinb, M., Andreas Rosenwaldb, A. & Brändlein, S. Early development of PAT-SM6 for the treatment of melanoma. Melanoma Res. 23, 264–275 (2013).
12. Quinn, G. P. & Keough, M. J. Experimental design and data analysis for biologists. (Cambridge University Press, 2002).
13. Ujvari, B. & Madsen, T. Do natural antibodies compensate for humoral immunosenescence in tropical pythons? Funct. Ecol. 25, 813–817 (2011).
14. Kreiss, A., Brown, G. K., Tovara, C. Lyons,A. B. & Woods, G. W. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils Sarcophilus harrisii immunized with killed cell preparations. Vaccine, doi: 10.1016/j.vaccine.2015.01.039 (2015).
15. Rouhi, R. P. et al. Autoantibodies against oxidized low-density lipoprotein in cerebral small vessel disease. Stroke 41, 2687–2689 (2010).
16. Melero, I. et al. Therapeutic vaccines for cancer an overview of an clinical trials. Nature Rev. Clin. Oncol. 11, 509–524 (2014).
17. Hamede, R. K. et al. Reduced effect of Tasmanian Devil Facial Tumor Disease at the disease front. Conserv. Biol. 26, 124–134 (2012).
18. Ujvari, B. & Belov K. Characterization of antibody V segment diversity in the Tasmanian devil (Sarcophilus harrisii). Vet. Immunol. Immunopathol. 167, 156–165 (2015).
19. Murchison, E. P. et al. Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell 148, 780–791 (2012).
20. Pfaffl, M. W., Tichopad, A., C. Prgomet, C. & Neuvians, T. P. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper - Excel-based tool using pair-wise correlations. Biotechnol. Letters 26, 509–515 (2004).
21. Pfaffl, M. W., Horgan, G. W. & Dempfle, L. Relative expression software tool REST for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucl. Acid. Res. 30, e36 (2002).

Acknowledgements

We are grateful to Jordan Charters for comments on the manuscript and to Gregory King-Brown and Peter Biro for statistical advice. Mark and Claire Walsh from Discovery Holiday Parks - Cradle Mountain - for provided accommodation and logistic support during field work. Forico Pty Ltd. facilitated land access and provided logistic support during our study. Field work was funded by an Eric Guiler Tasmanian Devil Research Grant through the Save the Tasmanian Devil Appeal of the University of Tasmania Foundation to R.H. and M.J. The work was also supported by ARC Discovery grants (DPI410103260, DPI110102731) to KB.
Author Contributions
B.U., R.H. and S.P. conducted the field work. B.U. conducted the molecular analyses. T.M. conducted the statistical analyses. T.M. prepared the figures. T.M. and B.U. wrote the manuscript. S.P., R.H., D.P., M.J. and K.B. contributed to the scientific discussion and revision of the article.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Ujvari, B. et al. Immunoglobulin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii). Sci. Rep. 6, 25093; doi: 10.1038/srep25093 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/